×

RNS Number : 9272I

Surgical Innovations Group PLC

17 December 2020

 

Surgical Innovations Group plc
("Surgical Innovations", "SI" or the "Company")

Nationwide US distribution agreement signed with Adler Instrument

$12m estimated value over five years

 

Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical  technology for minimally invasive surgery, announces a new nationwide distribution agreement with existing US distributor, Adler Instrument Company Inc. ("Adler"), for the Company's full range of handheld surgical instruments, consolidating its product distribution in the United States. The agreement brings a significant increase in the number of surgical territory managers promoting SI-branded products across the US. This five-year exclusive contract worth approximately $12m over its duration is effective from February 1, 2021, and will ensure the future success of the LogiCut and EcoCut scissor brands as well as providing a route into the US for the anticipated growth of new Logi-branded products.

 

Florida-based Adler, is a highly experienced distribution Company with access to nationwide coverage and are already working on converting a number of significant accounts from competing products to using the SI range of instruments. 

 

Chris Carter, CEO of Adler, said: "Our longstanding and successful relationship with Surgical Innovations in the south eastern United States has demonstrated that with quality products, Adler can meet healthcare needs and grow quickly and profitably. We are very excited to utilize our nationwide partnership coverage to grow Surgical Innovation business across the United States."

 

Adam Power, Group Development Director at SI, said: "Adler is SI's largest independent distributor and has previously sold SI branded product in just a small part of the United States. We are tremendously excited to work alongside them to grow our handheld instrument business across the country in territories that are essentially new to SI. This new relationship will open up the opportunity to compete for large nationwide and regional contracts which we have previously been unable to access."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

 

 

For further information please contact:  

 

Surgical Innovations Group plc	www sigroupplc com
David Marsh, CEO	Tel: 0113 230 7597
Charmaine Day, Co Sec & GFC
N+1 Singer (Nominated Adviser & Broker)	Tel: 020 7496 3000
Aubrey Powell (Corporate Finance)
Rachel Hayes (Corporate Broking)
Walbrook PR (Financial PR & Investor Relations)	Tel: 020 7933 8780 or [email protected]
Paul McManus / Lianne Cawthorne	Mob: 07980 541 893 / 07584 391 303

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

AGRFLFEAFFLRLII

Close

×

RNS Number : 9269I

DeepMatter Group PLC

17 December 2020

 

17 December 2020

 

DeepMatter Group plc

("DeepMatter", the "Company" or "the Group")

 

DeepMatter signs multi-year contract with Thieme Chemistry

 

DeepMatter Group plc, the AIM-quoted company focusing on digitising chemistry, is pleased to announce that it has signed a three-year contract with Thieme Chemistry, which is part of the Thieme Group, an award-winning international medical and science publisher serving health professionals and students for more than 130 years, for the supply of technical data services and access to the Group's proprietary algorithms.

 

The contract builds on a long-standing relationship between the two businesses, providing Thieme with access to DeepMatter's services and algorithms to ensure the quality of, and access to, their data.

 

Mark Warne, CEO of DeepMatter, commented: "We are delighted to have formalised our long-standing relationship with one of the world's leading scientific publishers and are proud of the role our data services and algorithms play in the quality of their world-renowned data. The theme of data quality in research is increasingly coming to the fore and through the breadth of our offerings we are well placed to meet the needs of the industry, from data-gathering at source through to publication."

 

Martin Spencker, Executive Vice President International Business of Thieme, commented: "We are committed to publishing only the highest quality of data and we believe that DeepMatter's tools provide us with the resources to do so. We are believers in the Company's offering and look forward to exploring the ways in which their technology can help us unlock further quality data."

 

For more information, please contact:

DeepMatter Group plc	T: 0141 548 8156
Mark Warne, Chief Executive Officer
C anaccord Genuity Limited (Nominated Advisor and Broker)	T:  020 7523 8000
Bobbie Hilliam / Angelos Vlatakis
Alma PR	T: 020 3405 0205
Caroline Forde / Harriet Jackson / Kieran Breheny	[email protected]

About DeepMatter Group plc  

DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. It has developed and is commercialising data rich platform technologies, including software and laboratory hardware, focused on applications to improve R&D productivity and discovery using Machine Learning / Artificial Intelligence. 

 

DeepMatter's technologies allow chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. They are designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster. 

 

Visit: www.deepmatter.io and follow @deepmattergroup

About Thieme Group

Thieme is a leading supplier of information and services contributing to the improvement of healthcare and health. Employing more than 1,000 staff, the family-owned company develops products and services in digital and other media for the medical and chemistry sectors. Operating internationally with offices in 11 cities worldwide, the Thieme Group works closely with a strong network of experts and partners. The products and services are based on the high-quality content of Thieme's 200 journals and 4,400 books. With solutions for professionals, Thieme supports relevant information processes in sciende, education, and patient care. The mission of the Thieme Group is to provide these markets with precisely the information, services, and products they need in their specific work situation and career. Providing top-quality services that are highly relevant to specific audiences, Thieme contributes to better healthcare and healthier lives. For more information about Thieme, please visit www.thieme.com .

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

CNTUNSKRRVUUAAA

Close

×

Neville Registrars is delighted to welcome iosBio Ltd as the newest addition to its list of client companies.

iosBio Ltd is a private British biotech company established in 2005.

Further information can be found on the Company's website: https://iosbio.com/

Close

×

RNS Number : 4662I

Intuitive Investments Group plc

14 December 2020

 

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. PLEASE SEE THE IMPORTANT NOTICE WITHIN THIS ANNOUNCEMENT.

 

Intuitive Investments Group plc

("IIG" or the "Company")

 

Admission to trading on AIM

& First Day of Dealings

 

Intuitive Investments Group plc (AIM: IIG), a closed-end investment company focussed on the life sciences sector, announces that its ordinary share capital comprising 40,419,200 ordinary shares of 1p each ("Ordinary Shares") has today been admitted to trading on AIM ("Admission") and that dealings in its Ordinary Shares will commence at 08.00 a.m today under the ticker "IIG".

 

In conjunction with Admission, a total of 39,250,000 new Ordinary Shares ("Placing Shares") were placed with institutional and other investors at a price of 20 pence per share (the "Placing Price") raising gross proceeds of £7.85 million for the Company.

 

Strand Hanson Limited as acted as the Company's Financial & Nominated Adviser and Turner Pope Investments (TPI) Ltd acted as the Company's Broker and Sole Bookrunner.

 

Key highlights

 

–  £7.85 million raised (before expenses) by the conditional placing of 39,250,000 new Ordinary Shares

–  The net proceeds of the Placing will be used by the Company:

– to invest in fast growing and / or high potential Life Sciences businesses, based predominantly in the UK, wider Europe and the US, chosen from an identified pipeline of investment opportunities

– investments will be focused on diagnostics and healthcare, medical devices, tools and technologies and bio-therapeutics and pharmaceuticals

–  The market capitalisation of the Company is expected to be £8.08 million on Admission

–  The Company's ISIN is GB00BNGFMW59, its SEDOL is BNGFMW5 and its LEI is 2138004A32UIY92WWR66

 

About Intuitive Investments Group plc

 

The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.

 

The Board and the Investment Team

 

The Directors believe that the Board and the Investment Team have vast experience in working within, investing in, and providing meaningful exits for, early stage life science companies. This collective experience covers hands-on board-level management, finance, commercialisation, research and development and operations, in addition to corporate finance activities across numerous investment rounds requiring managing every type of investment in both private companies and public markets.  The Investment Team is comprised of the Chairman, the CEO and the Chairman of the Advisory Panel.

 

David Evans, Executive Chairman

David Evans has over 27 years of experience in the Life Science sector, both in private companies and as a senior director of a number of public companies. David has facilitated 12 companies' transition to being publicly traded (directly or indirectly), has overseen four successful exits and has extensive experience chairing numerous UK public companies' boards. He has been actively engaged in a number of M&A transactions and has a record of high returns from personal investments in the Life Science sector.

 

Robert Naylor, Proposed CEO (appointment effective from 19 February 2021)

Robert Naylor has 24 years' experience in capital markets; most recently at Cenkos Securities plc as head of corporate finance and corporate broking in the investment funds team. Robert has advised a number of Life Science companies.

 

Malcolm Gillies, Non-Executive Director

Malcolm Gillies is a lawyer by background, having worked as a senior corporate partner for over 10 years. He has since taken numerous director roles with Life Science focussed public companies.

 

Cormac Kilty, Non-Executive Director

Cormac Kilty has founded a number of Life Science and Diagnostics companies and has acted as a director of many Life Science companies.

 

Colin Willis, Non-Executive Director

Colin Willis specialises in venture capital, with over 24 years of experience in the field. He has set up three venture capital companies providing substantial returns to investors.

 

Advisory Panel

 

The Company has established an Advisory Panel with a wealth of knowledge and experience in the Life Science and Diagnostics sectors to support the Board's identification, assessment and appraisal of potential investment opportunities and to provide general guidance to the Board where required. The Company's Advisory Panel comprises:

 

Dr. Stewart White, (Advisory Panel Chair) has acted as Chairman and CEO of numerous Life Science companies. Stewart is a visiting professor at the University of Glasgow and has a PhD in Bioprocessing.

 

Julian Baines is CEO of EKF Diagnostics Holdings plc (AIM:EKF) and holds an MBE for services in the Life Science sector.

 

Ron Long has held a number of positions as CEO and Chairman of Life Science companies and several start-up businesses.

 

Per Matsson has experience in senior positions in various Life Science R&D departments. He is also an associate professor in Veterinary Science and holds a PhD in biology.

 

Alastair Smith, CEO of Avacta Group plc (AIM:AVCT), was previously a professor of Molecular Biophysics and has a PhD in Physics.

 

The Directors believe the Board and Advisory Panel have the requisite skills to determine viable and investable Life Science companies that have the chance to grow and, ultimately, create value by improving human health.

 

Investing Strategy

 

– The Company has a multi-dimensional investment strategy to capitalise on significant opportunities in growth (Series A and B), special situations and public companies, with a focus on early and late stage venture capital.

– IIG expects to be able to beneÞt from access to the Board's identiÞed pipeline of over 16 potential investment opportunities. It is also envisaged that, due to the demand that currently exists for post-seed venture capital in the European and US Life Sciences market, the potential pipeline available to the Company will continue to increase.

– The Company's portfolio is expected to comprise approximately 10-12 holdings, with no single investment representing more than 15% of the Company's NAV.

– IIG has a low-cost model. The Company will be internally managed, with no material remuneration to the Chairman other than a performance related incentive fee.

 

David Evans, Executive Chairman of IIG, commented:

" We are very pleased to be joining the AIM market today. With our combined experience and demonstrative track record in the sector, we will look to the future and invest in fast growing and / or high potential life sciences businesses, based predominantly in the UK, wider Europe and the US, chosen from an identified pipeline of investment opportunities .

 

"We will seek investments focused on diagnostics and healthcare, medical devices, tools and technologies and bio-therapeutics and pharmaceuticals. IIG's proposition is based on my belief that through the skillful deployment of capital, we can advance the growth of companies with greater certainty than otherwise might be the case and provide a superior return to other alternative investment opportunities for investors."

 

The Company's Admission Document is available here: www.iigplc.com

 

For further information, please contact:

 

Intuitive Investments Group plc
David Evans		Via Walbrook PR
Strand Hanson Limited – Nominated Adviser		+44 (0) 20 7409 3494
James Harris / James Dance / James Bellman
Turner Pope Investments (TPI) Ltd – Broker		+44 (0) 20 3657 0050
Ben Turner / James Pope / Andrew Thacker
Walbrook PR Limited – Media & Investor Relations	+44 (0)20 7933 8780 or [email protected]
Paul McManus		+44 (0) 7980 541 893

 

Important Information

This announcement does not constitute, or form part of, any offer or invitation to sell, allot or issue, or any solicitation of any offer to purchase or subscribe for, any securities in the Company in any jurisdiction nor shall it, or any part of it, or the fact of its distribution, form the basis of, or be relied on in connection with or act as an inducement to enter into, any contract or commitment therefor. 

 

The information contained in this announcement is for background purposes only and does not purport to be full or complete.. No reliance may or should be placed by any person for any purpose on the information contained in this announcement or its accuracy, fairness or completeness. The information in this announcement is subject to change.

 

Recipients of this announcement who are considering subscribing for or acquiring Ordinary Shares following publication of the Admission Document are reminded that any such acquisition or subscription must be made only on the basis of the information contained in the final Admission Document.  No reliance may be placed, for any purpose whatsoever, on the information or opinions contained in this announcement or on its completeness. To the fullest extent permitted by applicable law or regulation, no undertaking, representation or warranty, express or implied, is given by or on behalf of the Company, Strand Hanson Limited ("Strand Hanson") or Turner Pope Investments (TPI) Ltd ("Turner Pope"), or their respective parent or subsidiary undertakings or the subsidiary undertakings of any such parent undertakings or any of their respective directors, officers, partners, employees, agents, affiliates, representatives or advisers or any other person as to the accuracy, sufficiency, completeness or fairness of the information, opinions or beliefs contained in this announcement and, save in the case of fraud, no responsibility or liability is accepted by any of them for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred, howsoever arising, from any use, as a result of the reliance on, or otherwise in connection with this announcement

 

Strand Hanson, which is a member of the London Stock Exchange plc, is authorised and regulated in the UK by the Financial Conduct Authority. Strand Hanson is acting as nominated adviser (for the purposes of the AIM Rules) exclusively for the Company in connection with the Placing and Admission. Strand Hanson is not acting for, and will not be responsible to, any person other than the Company for providing the protections afforded to its customers or for advising any other person on the contents of this announcement or on any transaction or arrangement referred to in this announcement or any acquisition of Ordinary Shares in the Company. Strand Hanson's responsibilities as the Company's nominated adviser under the AIM Rules are owed solely to the London Stock Exchange and are not owed to the Company, any Director or to any other person. No representation or warranty, express or implied, is made by Strand Hanson as to, and no liability is accepted by Strand Hanson in respect of, any of the contents of this announcement or for the omission of any material from this announcement, for which it is not responsible.

 

Turner Pope, which is authorised and regulated in the UK by the Financial Conduct Authority. Turner Pope is acting as broker (for the purposes of the AIM Rules) exclusively for the Company in connection with the Placing and Admission. Turner Pope is not acting for, and will not be responsible to, any person other than the Company for providing the protections afforded to its customers or for advising any other person on the contents of this document or on any transaction or arrangement referred to in this document or any acquisition of Ordinary Shares in the Company. No representation or warranty, express or implied, is made by Turner Pope as to, and no liability is accepted by Turner Pope in respect of, any of the contents of this announcement or for the omission of any material from this announcement, for which it is not responsible.

 

This announcement is only addressed to, and directed at, persons in member states of the European Economic Area who are qualified investors within the meaning of Article 2(e) of the Prospectus Regulation (EU 2017/1129) ("Qualified Investors"). In addition, in the United Kingdom, this announcement is addressed to and directed only at Qualified Investors who are: (i) persons having professional experience in matters relating to investments, i.e., investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO"); (ii) high net-worth companies, unincorporated associations and other bodies within the meaning of Article 49 of the FPO; and (iii) persons to whom it is otherwise lawful to communicate it to.  It is not intended that this announcement be distributed or passed on, directly or indirectly, to any other class of person and in any event, and under no circumstances should persons of any other description rely on or act upon the contents of this announcement.

 

This announcement does not constitute, and may not be used for the purposes of, an offer or an invitation to apply for any Ordinary Shares by any person: (i) in any jurisdiction in which such offer or invitation is not authorised; or (ii) in any jurisdiction in which the person making such offer or invitation is not qualified to do so; or (iii) to any person to whom it is unlawful to make such offer or invitation. In particular, this document is not for publication or distribution, in whole or in part, directly or indirectly, in or into the United States (including its territories and possessions, any State of the United States and the District of Columbia) (collectively, the "United States"), Canada, the Republic of South Africa, Australia, the Republic of Ireland or Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. The Ordinary Shares have not been and will not be registered under securities legislation of any province or territory of the United States, Canada, the Republic of South Africa, Australia, the Republic of Ireland or Japan or in any country, territory or possession where to do so may contravene local securities law or regulations. Accordingly, subject to certain exemptions, the Ordinary Shares may not be offered or sold directly or indirectly in or into the United States, Canada, the Republic of South Africa, Australia, the Republic of Ireland or Japan or to any national, resident or citizen of the United States, Canada, the Republic of South Africa, Australia, the Republic of Ireland or Japan. The distribution of this announcement in other jurisdictions may be restricted by law and therefore persons into whose possession this document comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities law of any such jurisdiction.

 

The Ordinary Shares have not been nor will they be registered under the U.S. Securities Act or with any securities regulatory authority of any state or other jurisdiction of the United States. In addition, the Company has not registered and will not register under the U.S. Investment Company Act. The Ordinary Shares have not been approved or disapproved by the U.S. Securities and Exchange Commission, any state securities commission in the United States or any other U.S. regulatory authority, nor have any of the foregoing authorities passed upon or endorsed the merits of the offering or the issue of the Ordinary Shares or the accuracy or adequacy of this document. Any representation to the contrary is a criminal offence in the United States and the re-offer or resale of any of the Ordinary Shares in the United States may constitute a violation of U.S. law.

 

This announcement contains certain statements that are, or may be, forward looking statements with respect to the financial condition, results of operations, business achievements and/or investment strategy of the Company. Such forward looking statements are based on the Company's board of directors' (the "Board") expectations of external conditions and events, current business strategy, plans and the other objectives of management for future operations, and estimates and projections of the Company's financial performance.  Though the Board believes these expectations to be reasonable at the date of this announcement they may prove to be erroneous.  Forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, achievements or performance of the Company, or the industry in which the Company operates, to be materially different from any future results, achievements or performance expressed or implied by such forward looking statements.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

AIMKZMMZNFDGGZM

Close

×

RNS Number : 5181I

British Honey Company PLC (The)

14 December 2020

 

14.12.20.

 

The British Honey Company plc

( " British Honey", " BHC" or the " Company")

BHC Listing elevated to Apex segment of AQSE Growth Market

Further to the announcement by The Aquis Stock Exchange earlier today that proposed changes to the rules and regulations of its subsidiary, The Aquis Stock Exchange (AQSE) Growth Market, are now in force, BHC, the producer of premium British honey, honey-infused spirits and alcohol sanitiser products, is delighted to announce that its listing on the AQSE Growth Market has been elevated to the "Apex" segment of the Exchange.

 

From today, the AQSE Growth Market will be divided into two segments, "Access" and "Apex" with differing levels of Admission criteria in order to provide appropriate support across companies' growth cycles. The "Access" market will focus on earlier stage growth companies while "Apex" will serve larger, more established businesses, such as BHC.

 

BHC, which listed on the AQSE Growth Market in March this year, satisfies all the criteria required by the "Apex" segment, comprising:

 

· A market capitalisation of at least £10 million

· At least 25% of its issued share capital in public hands

· At least two market-makers

· A minimum two years' trading record

· Adoption of a recognized Corporate Governance Code (the QCA Code)

 

The rule changes have been developed in consultation with companies listed on the Exchange and their advisers to enhance the operational efficiencies of the Market and to increase support from both retail and institutional investors by applying core values including transparency and innovation, whilst ensuring a robust regulatory framework.

 

Commenting on BHC's move up to "Apex", Michael Williams, CEO, said:

"We are delighted to join the Apex segment of the Aquis Stock Exchange Growth Market. Since our IPO in March this year, we have been most impressed with how innovative, knowledgeable and helpful everyone at the AQSE has been, contributing greatly to our life as a public company. The new rules and regulations will also help to attract even more institutional and retail investors to the market by making it more efficient, more effective and more accessible to them and to growth companies seeking a listing. 

 

"We also look forward to the introduction of the forthcoming Market Maker Incentive Scheme in the New Year which will help to boost liquidity and improve even further the functioning of the AQSE Growth Market."

 

 

Enquiries:

British Honey Michael Williams, CEO Brooke Wiseman, Marketing Director	Tel: +44 (0)7976 559243 Email: [email protected] Web:   https://britishhoney.co.uk/
finnCap – AQSE Corporate Adviser & Joint Broker Carl Holmes / Matthew Radley (corporate finance)   Richard Chambers (ECM)	Tel: +44 (0)20 7220 0500
Stanford Capital Partners – Joint Broker Patrick Claridge / John Howes / Bob Pountney	Tel: +44 (0)20 3815 8880
Walbrook PR Limited – Financial PR Paul Vann / Nick Rome / Nicholas Johnson	Tel: +44 (0)20 7933 8780   +44 (0)7768 807631   [email protected]

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NEXFFFSWLESSEEE

Close

×

Neville Registrars is delighted to welcome Intuitive Investments Group plc as the newest addition to its list of client companies.

Intuitive Investments seeks to provide investors with exposure to a portfolio of investments concentrating on fast growing and/or high potential life sciences businesses operating predominantly in the UK, continental Europe and the US.

Further information can be found on the Company's website: https://iigplc.com/

Close

×

Neville Registrars is delighted to welcome Volvere plc as the newest addition to its list of client companies.

Volvere is an industrial holding company that invests in or acquires companies which require growth capital.

Further information can be found on the Company's website: https://www.volvere.co.uk/

Close

×

Neville Registrars is delighted to welcome NMT Group Limited as the newest addition to its list of client companies.

NMT is a medical devices company that developed a safety syringe to prevent needlestick injury. 

Further information can be found as follows: https://www.volvere.co.uk/current-portfolio/nmt-group.aspx

Close

×

Neville Registrars is delighted to welcome Craven House Capital Plc as the newest addition to its list of client companies.

Craven House Capital is a merchant bank in the 18th and 19th Century context of the term.

Further information can be found on the Company's website: http://www.cravenhousecapital.com/

 

Close

×

Neville Registrars is delighted to welcome Eco Equity Limited as the newest addition to its list of client companies.

Eco Equity is a pharmaceutical supplier of medicinal cannabis.

Further information can be found on the Company's website: https://www.eco-equity.com/

Close